Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines that correct abnormal gene expression to treat serious diseases, with an initial emphasis on oncology [1][3] - The company utilizes its proprietary Gene Traffic Control® platform to identify and validate drug targets within the chromatin regulatory system, aiming to transform the treatment landscape for various diseases [3] Conference Participation - Foghorn Therapeutics will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 3:30 p.m. ET, with CEO Adrian Gottschalk as the presenter [2] - The company will also participate in one-on-one meetings during the Jefferies conference [2] - Additionally, Foghorn will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 3:20 p.m. ET, again featuring CEO Adrian Gottschalk [2] - One-on-one meetings will also be held during the Goldman Sachs conference [2] Company Overview - Foghorn Therapeutics is engaged in discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system [3] - The company is developing multiple product candidates specifically in the oncology sector [3] - More information about the company can be found on its website and social media platforms [3]